
Results
12
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
12 companies
Natera
Market Cap: US$38.7b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$270.36
7D
7.2%
1Y
92.9%
Teva Pharmaceutical Industries
Market Cap: US$40.2b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$34.46
7D
8.8%
1Y
119.4%
Merck
Market Cap: US$315.6b
Operates as a healthcare company worldwide.
MRK
US$127.77
7D
-3.1%
1Y
58.2%
AbbVie
Market Cap: US$433.0b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$245.10
7D
-6.9%
1Y
23.4%
Travere Therapeutics
Market Cap: US$5.1b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$54.98
7D
-1.7%
1Y
229.6%
Sotera Health
Market Cap: US$5.1b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$17.99
7D
1.3%
1Y
60.8%
Ligand Pharmaceuticals
Market Cap: US$5.8b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$292.04
7D
-1.4%
1Y
116.1%
SIGA Technologies
Market Cap: US$230.2m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.21
7D
-3.9%
1Y
-51.4%
Mesa Laboratories
Market Cap: US$584.4m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$104.43
7D
3.3%
1Y
81.8%
Waters
Market Cap: US$36.8b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$374.74
7D
-2.4%
1Y
33.3%
BioLife Solutions
Market Cap: US$1.6b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$32.15
7D
0.5%
1Y
55.1%
Repligen
Market Cap: US$8.3b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$147.06
7D
1.2%
1Y
26.9%